JP6946313B2 - 血液系物質からタンパク質を抽出する方法 - Google Patents
血液系物質からタンパク質を抽出する方法 Download PDFInfo
- Publication number
- JP6946313B2 JP6946313B2 JP2018541324A JP2018541324A JP6946313B2 JP 6946313 B2 JP6946313 B2 JP 6946313B2 JP 2018541324 A JP2018541324 A JP 2018541324A JP 2018541324 A JP2018541324 A JP 2018541324A JP 6946313 B2 JP6946313 B2 JP 6946313B2
- Authority
- JP
- Japan
- Prior art keywords
- chromatography
- supernatant
- salt
- protein
- paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/303—Extraction; Separation; Purification by precipitation by salting out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3814—Affinity chromatography of the substrate or co-factor - enzyme type
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
- B01D61/027—Nanofiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/16—Diafiltration
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Water Supply & Treatment (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims (16)
- 血液系物質からタンパク質生成物を生成する方法であって:
前記血液系物質に第1塩を加えて第1中間体を生成するステップであって、前記塩は、前記第1中間体の11−20wt%を成す、ステップと;
前記第1中間体を分離して第1上清と第1ペーストを生成するステップと;
前記第1上清に第2塩を加えて第2中間体を生成するステップであって、前記塩は前記第2中間体の15−30wt%を成す、ステップと;
前記第2中間体を分離して、第2上清と第2ペーストを生成するステップと;
前記第2上清を第1クロマトグラフィープロセスにより分離して、第1フロースルーと第3中間体を生成するステップと;
前記第3中間体を第2クロマトグラフィープロセスにより分離して、第2フロースルーと前記タンパク質生成物を含有する溶離液を生成するステップとを含み、
前記タンパク質生成物は、前記第2中間体から単独で得られ、前記タンパク質生成物の収率は70%以上であり、
前記方法が、複数の塩分別ステップ、少なくとも1回のダイアフィルトレーション、及び複数の精製ステップのみからなり、
前記タンパク質生成物が、アルファ1−プロテイナーゼインヒビター及び/又はアルブミンである、方法。 - 前記血液系物質は、原料血漿、新鮮凍結血漿、回収血漿、および再利用血漿の少なくとも1つを含む、請求項1に記載の方法。
- 前記血液系物質は、分画血液、分画血漿、Cohn分画、NitschmannおよびKistlerの分画、Cohnプロセスの中間物質、NitschmannおよびKistlerプロセスの中間物質、ポリエチレングリコール分画の中間物質、ならびにカプリル酸塩分画の中間物質の少なくとも1つを含む、請求項1に記載の方法。
- 前記第1塩には、クエン酸塩、酢酸塩、およびグルコン酸塩の少なくとも1つが含まれる、請求項1〜3のいずれか一項に記載の方法。
- 前記第1塩は前記第2塩と同じである、請求項1〜4のいずれか一項に記載の方法。
- 前記第1中間体を分離して前記第1上清と前記第1ペーストを生成するステップは、前記第1中間体を遠心分離するステップを含む、請求項1〜5のいずれか一項に記載の方法。
- 前記第1中間体を分離して前記第1上清と前記第1ペーストを生成するステップは、前記第1中間体を濾過するステップを含む、請求項1〜5のいずれか一項に記載の方法。
- 前記第1上清と前記第2上清の少なくとも1つを濾過プロセスにかける、請求項1〜7のいずれか一項に記載の方法。
- 前記第1クロマトグラフィープロセスは、ゲル浸透クロマトグラフィー、サイズ排除クロマトグラフィー、および拡張床吸着クロマトグラフィーの少なくとも1つを含む、請求項1〜8のいずれか一項に記載の方法。
- 前記第1クロマトグラフィープロセスは、陽イオン交換クロマトグラフィー、陰イオン交換クロマトグラフィー、疎水性相互作用クロマトグラフィー、ヒドロキシアパタイトクロマトグラフィー、フルオロアパタイトクロマトグラフィー、または固定化金属イオンアフィニティークロマトグラフィーの少なくとも1つを含む、請求項1〜8のいずれか一項に記載の方法。
- 前記第1クロマトグラフィープロセスと前記第2クロマトグラフィープロセスは異なる、請求項1〜10のいずれか一項に記載の方法。
- 前記第1ペースト、前記第2ペースト、前記第1フロースルー、および前記第2フロースルーの少なくとも1つから第2タンパク質生成物を単離するステップをさらに含む、請求項1〜11のいずれか一項に記載の方法。
- 前記第2上清を第1クロマトグラフィーにより分離して第1フロースルーと第3中間体を生成する前記ステップの前に、さらに、
第2塩を第2上清に添加して第2中間体−1を製造し、ここで前記塩は、前記第2中間体−1の15−30wt%をなす、前記第2中間体−1を分離して第2上清−1と第2ペースト−1とを生成する、ことを含む、ここで、第1クロマトグラフィーによって分離される第2上清が前記第2上清−1である、請求項1〜12のいずれか一項に記載の方法。 - タンパク質を不安定化するに足る数の、前記タンパク質内のジスルフィド結合を破壊する工程を含まない、請求項1〜13のいずれか一項に記載の方法。
- 血液系物質から生成物を抽出する方法であって:
血液系物質を得るステップと;
前記血液系物質を第1クロマトグラフィープロセスにより分離して、第1フロースルーと第1中間体を生成するステップと;
前記第1中間体に第1塩を加えて第2中間体を生成するステップであって、前記第1塩は前記第2中間体の11−13wt%を成す、ステップと;
前記第2中間体を分離して、第1上清と第1ペーストを生成するステップと;
前記第1上清に第2塩を加えて第3中間体を生成するステップであって、前記第1塩と前記第2塩は前記第3中間体の21−23wt%を成す、ステップと;
前記第3中間体を分離して、第2上清と第2ペーストを生成するステップと;
前記第2上清を第2クロマトグラフィープロセスにより分離して、第2フロースルーと前記生成物を含有する溶離液を生成するステップとを含み、
前記方法が、複数の塩分別ステップ、少なくとも1回のダイアフィルトレーション、及び複数の精製ステップのみからなり、
前記生成物が、アルファ1−プロテイナーゼインヒビター及び/又はアルブミンである、方法。 - タンパク質を不安定化するに足る数の、前記タンパク質内のジスルフィド結合を破壊する工程を含まない、請求項15に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021150229A JP2022000442A (ja) | 2016-02-03 | 2021-09-15 | 血液系物質からタンパク質を抽出する方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662290638P | 2016-02-03 | 2016-02-03 | |
US62/290,638 | 2016-02-03 | ||
PCT/US2017/016595 WO2017136785A1 (en) | 2016-02-03 | 2017-02-03 | Methods for extracting proteins from a blood-based material |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021150229A Division JP2022000442A (ja) | 2016-02-03 | 2021-09-15 | 血液系物質からタンパク質を抽出する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019513119A JP2019513119A (ja) | 2019-05-23 |
JP6946313B2 true JP6946313B2 (ja) | 2021-10-06 |
Family
ID=59501069
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018541324A Active JP6946313B2 (ja) | 2016-02-03 | 2017-02-03 | 血液系物質からタンパク質を抽出する方法 |
JP2021150229A Pending JP2022000442A (ja) | 2016-02-03 | 2021-09-15 | 血液系物質からタンパク質を抽出する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021150229A Pending JP2022000442A (ja) | 2016-02-03 | 2021-09-15 | 血液系物質からタンパク質を抽出する方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US11028125B2 (ja) |
EP (1) | EP3411383A4 (ja) |
JP (2) | JP6946313B2 (ja) |
KR (1) | KR20180101583A (ja) |
CN (1) | CN108779144B (ja) |
AU (1) | AU2017214678B2 (ja) |
CA (1) | CA3012694A1 (ja) |
MX (1) | MX2018009331A (ja) |
WO (1) | WO2017136785A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3362464B1 (en) * | 2015-10-15 | 2021-04-28 | Plasma Technologies LLC | Methods for extracting proteins from blood plasma |
CN108779144B (zh) | 2016-02-03 | 2022-06-14 | 普莱泽玛科技有限公司 | 从血液原料中提取蛋白质的方法 |
CN109678969B (zh) * | 2018-12-29 | 2020-02-07 | 北京东方百泰生物科技有限公司 | 一种CTLA4-Ig融合蛋白的纯化方法 |
US10836790B1 (en) * | 2019-09-20 | 2020-11-17 | Plasma Technologies, Llc | Therapeutic protein compositions and methods |
US10815270B1 (en) * | 2019-09-20 | 2020-10-27 | Plasma Technologies, Llc | Compositions and methods for high efficiency protein precipitation |
CN112830953A (zh) * | 2019-11-22 | 2021-05-25 | 中国科学院大连化学物理研究所 | 一种干细胞培养液中提取活性蛋白的方法 |
AU2021355325A1 (en) * | 2020-04-10 | 2022-11-03 | Plasma Technologies, Llc | Compositions and methods for simplified high efficiency isolation of proteins |
CN112409476B (zh) * | 2020-08-13 | 2022-03-29 | 中元汇吉生物技术股份有限公司 | 四种血液来源蛋白的纯化方法 |
CN118055798A (zh) | 2021-10-01 | 2024-05-17 | 瑞士杰特贝林生物制品有限公司 | 改进的纯化方法 |
CN114395031A (zh) * | 2022-01-24 | 2022-04-26 | 华南师范大学 | 罗非鱼血清转铁蛋白的纯化方法及其应用 |
CN114835801B (zh) * | 2022-06-20 | 2023-09-22 | 华润博雅生物制药集团股份有限公司 | 一种c1酯酶抑制剂及其制备方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2390074A (en) | 1942-02-09 | 1945-12-04 | Research Corp | Protein product and process |
US4404132A (en) | 1980-05-27 | 1983-09-13 | Cutter Laboratories, Inc. | Blood coagulation promoting product |
JPS584728A (ja) * | 1981-05-01 | 1983-01-11 | メデイカル・リサ−チ・インステイチユ−ト・オブ・サンフランシスコ・コ−ポレ−シヨン | α−1−抗トリプシンの精製 |
US4639513A (en) * | 1984-02-02 | 1987-01-27 | Cuno Inc. | Intravenously injectable immunoglobulin G (IGG) and method for producing same |
US4486282A (en) | 1983-02-22 | 1984-12-04 | University Patents, Inc. | Precipitation of proteins from salt-containing proteinaceous fluids employing a desalting treatment, and use thereof in selective plasmapheresis |
US4697003A (en) | 1985-11-01 | 1987-09-29 | Miles Laboratories, Inc. | Method of preparing alpha-1-proteinase inhibitor |
US5177194A (en) | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
GB9705810D0 (en) | 1997-03-20 | 1997-05-07 | Common Services Agency | Intravenous immune globulin |
US6955917B2 (en) * | 1997-06-20 | 2005-10-18 | Bayer Healthcare Llc | Chromatographic method for high yield purification and viral inactivation of antibodies |
AUPP971399A0 (en) | 1999-04-12 | 1999-05-06 | Life Therapeutics Limited | Separation of plasma components |
SE0001128D0 (sv) * | 2000-03-30 | 2000-03-30 | Amersham Pharm Biotech Ab | A method of producing IgG |
US6881731B1 (en) | 2000-10-23 | 2005-04-19 | Shanbrom Technologies, Llc | Enhancers for microbiological disinfection |
US7297716B2 (en) | 2000-10-23 | 2007-11-20 | Shanbrom Technologies, Llc | Enhanced production of blood components, blood cells and plasma without freezing |
ES2184594B1 (es) | 2001-01-17 | 2004-01-01 | Probitas Pharma Sa | Procedimiento para la produccion de gammaglobulina g humana inactivada de virus. |
EP1363616A1 (en) | 2001-02-07 | 2003-11-26 | Shanbrom Technologies, LLC | Carboxylic acid such as citric acid for disinfecting or enhancing the production of blood products such as plasma, cryoprecipitate or/and platelet |
BRPI0412835A (pt) * | 2003-08-12 | 2006-09-26 | Octapharma Ag | processo para preparação de uma solução de alfa-1-antitripsina |
US20070049732A1 (en) | 2005-09-01 | 2007-03-01 | Zurlo Eugene J | Ultra-high yield intravenous immune globulin preparation |
US8293242B2 (en) * | 2005-09-01 | 2012-10-23 | Plasma Technologies, Llc | Ultra-high yield of alpha-1-anti-trypsin |
US7879332B2 (en) * | 2005-09-01 | 2011-02-01 | Plasma Technologies, Llc | Ultra-high yield intravenous immune globulin preparation |
GB0524432D0 (en) | 2005-11-30 | 2006-01-11 | Nhs Blood & Transplant | Method |
US20110237781A1 (en) | 2008-07-18 | 2011-09-29 | Talecris Biotherapeutics, Inc. | Method of preparing alpha-1 proteinase inhibitor |
US8063189B2 (en) * | 2009-04-13 | 2011-11-22 | Bristol-Myers Squibb Company | Protein purification by citrate precipitation |
US9624262B2 (en) * | 2011-09-16 | 2017-04-18 | Ge Healthcare Bioprocess R&D Ab | Plasma protein fractionation by sequential polyacid precipitation |
CN102599332B (zh) * | 2012-03-09 | 2014-07-30 | 上海杰隆生物制品股份有限公司 | 一种利用禽血生产低灰分禽血浆蛋白粉的方法 |
EP3362464B1 (en) * | 2015-10-15 | 2021-04-28 | Plasma Technologies LLC | Methods for extracting proteins from blood plasma |
CN108779144B (zh) | 2016-02-03 | 2022-06-14 | 普莱泽玛科技有限公司 | 从血液原料中提取蛋白质的方法 |
-
2017
- 2017-02-03 CN CN201780009926.9A patent/CN108779144B/zh active Active
- 2017-02-03 AU AU2017214678A patent/AU2017214678B2/en active Active
- 2017-02-03 EP EP17748315.3A patent/EP3411383A4/en active Pending
- 2017-02-03 KR KR1020187024161A patent/KR20180101583A/ko not_active Application Discontinuation
- 2017-02-03 WO PCT/US2017/016595 patent/WO2017136785A1/en active Application Filing
- 2017-02-03 MX MX2018009331A patent/MX2018009331A/es unknown
- 2017-02-03 JP JP2018541324A patent/JP6946313B2/ja active Active
- 2017-02-03 CA CA3012694A patent/CA3012694A1/en active Pending
- 2017-08-10 US US16/072,175 patent/US11028125B2/en active Active
-
2021
- 2021-05-13 US US17/320,086 patent/US20210261608A1/en active Pending
- 2021-09-15 JP JP2021150229A patent/JP2022000442A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022000442A (ja) | 2022-01-04 |
CN108779144A (zh) | 2018-11-09 |
AU2017214678B2 (en) | 2024-02-01 |
JP2019513119A (ja) | 2019-05-23 |
KR20180101583A (ko) | 2018-09-12 |
US20190055282A1 (en) | 2019-02-21 |
US11028125B2 (en) | 2021-06-08 |
AU2017214678A1 (en) | 2018-08-16 |
EP3411383A4 (en) | 2019-08-14 |
MX2018009331A (es) | 2018-11-09 |
CN108779144B (zh) | 2022-06-14 |
EP3411383A1 (en) | 2018-12-12 |
CA3012694A1 (en) | 2017-08-10 |
WO2017136785A1 (en) | 2017-08-10 |
US20210261608A1 (en) | 2021-08-26 |
AU2017214678A2 (en) | 2018-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6946313B2 (ja) | 血液系物質からタンパク質を抽出する方法 | |
JP3094167B2 (ja) | 免疫血清グロブリンの精製方法 | |
US11719690B2 (en) | Methods for extracting A1P1 and albumin from blood plasma | |
CN106459140B (zh) | 用于纯化免疫球蛋白的方法 | |
US10562958B2 (en) | Method for producing injectable formulations of blood-derived protein materials, and materials obtained using said method | |
US11884702B2 (en) | Systems and methods for process scale isolation of immunoglobulin G | |
US20210363179A1 (en) | Method for removing fxi when purifying plasma proteins | |
US20220402969A1 (en) | Methods for Extracting Proteins from a Blood-Based Material | |
US20180305401A1 (en) | Processes for purifying proteins from plasma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181005 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210409 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210817 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210915 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6946313 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |